key: cord-0978177-4mwryifq
authors: McCarthy, Cormac; Savinelli, Stefano; Feeney, Eoin R.; Butler, Marcus W.; O'Broin, Cathal; Ryan, Silke; O'Neill, Lorraine; Murphy, David J.; Gallagher, Charles G.; McKone, Edward F.; Waqas, Sarmad; Cotter, Aoife; Doran, Peter; Keane, Michael P.; Mallon, Patrick W.
title: Tocilizumab therapy in individuals with COVID‐19 infection and hyperinflammatory state
date: 2020-07-21
journal: Respirology
DOI: 10.1111/resp.13912
sha: b3c4e2b407f4d01a0600ea4cb814ffbec861b21c
doc_id: 978177
cord_uid: 4mwryifq

nan

To the Editors:

Coronavirus disease 2019 (COVID-19) infection, an illness caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), has spread rapidly worldwide resulting in a global pandemic. A subset of individuals with COVID-19 present with severe pneumonia, evolving in some cases to acute respiratory distress syndrome (ARDS), coupled with clinical and biochemical features of hyperinflammatory syndrome, and characterized by increased levels of ferritin, C-reactive protein (CRP), interleukin (IL)-6 and D-dimer. 1-3 These acute phase proteins may reflect circulating IL-6, possibly a key driver of a dysregulated inflammatory response in COVID-19. 2 Tocilizumab is a humanized monoclonal antibody targeting the IL-6 receptor. Used to treat inflammatory arthritis, tocilizumab has been effectively used to treat both secondary hemophagocytic lymphohistiocytosis, an autoimmune-based hyperinflammatory syndrome, as well as cytokine release syndrome, a side effect of chimeric antigen receptor T (CAR-T) cell immunotherapy. 4, 5 Currently, published data on the use of tocilizumab in the setting of COVID-19 infection is scarce. 6, 7 We report data on six individuals with severe COVID-19 pneumonia and hyperinflammatory state treated with tocilizumab, with outcomes suggesting a potential role for tocilizumab in specific clinical circumstances in COVID-19 infection that could inform future clinical trial design.

Between 7 March and 7 April 2020, 193 patients were admitted with confirmed COVID-19 infection to St. Vincent's University Hospital, an 836-bed tertiary referral centre in Dublin, Ireland. All patients enrolled into the All-Ireland Infectious Diseases Cohort Study, a multicentre, prospective cohort study. This study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practices, and was approved by the St. Vincent's Healthcare Group Research Ethics Committee. All patients who agreed to participate provided written informed consent.

Patients were considered for tocilizumab based on the presence of severe COVID-19 pneumonia and evidence of a hyperinflammatory response. Cases were discussed at multidisciplinary team (MDT) meetings involving infectious disease, pulmonary, critical care and rheumatology physicians. Individuals with evidence of disease progression manifested by moderate to severe respiratory failure as defined by a ratio of peripheral capillary oxygen saturation compared to fraction of inspired oxygen (SpO 2 :FiO 2 ) of ≤315 mm Hg, 8 progression of or new pulmonary infiltrates on chest imaging and evidence of hyperinflammation (including three of temperature >38 C in the past 48 h, D-dimer >1.5 μg/mL and elevated levels of CRP, ferritin, lactate dehydrogenase (LDH) or fibrinogen) were considered for MDT discussion. Use of tocilizumab was avoided in those with imminent requirement for intubation/mechanical ventilation, known immunosuppression, active malignancy, uncontrolled bacterial infection, liver transaminases 10 times the normal values or history of significant gastrointestinal ulcerative disease.

Of the 193 cases, 8 (4.1%) were considered for tocilizumab therapy of whom 6 patients were treated with a single dose of intravenous tocilizumab at 8 mg/ kg (maximum dose: 800 mg). The reasons that two patients did not receive tocilizumab after multidisciplinary discussion were severe frailty with multiple comorbidities in one patient and rapid progression of respiratory failure requiring imminent intubation in the other patient. Baseline demographic/clinical characteristics of the six treated patients are outlined in Table 1 Table S1 (Supplementary Information)).

Following tocilizumab, we observed a rapid decline in inflammatory markers and decreased oxygen requirements in all patients. Two patients initially deteriorated following tocilizumab. Both were admitted to the intensive care unit (ICU) and maintained on continuous positive airway pressure ventilatory support, being discharged from the ICU after 2 and 3 days, Table 1 Demographics, clinical characteristics and radiological Continued respectively, without the need for mechanical ventilation. All patients were discharged home at a median of 7 days (IQR: 7-8 days) post tocilizumab. One patient was readmitted to the hospital 2 days after discharge, 9 days after tocilizumab administration, due to an exacerbation of COPD complicated by bacterial pneumonia. This individual received antibiotics in hospital and was discharged to go home 7 days thereafter. This report describes the clinical outcomes of six patients with COVID-19 pneumonia and hyperinflammatory response treated with tocilizumab in the pre-ICU setting and suggests favourable outcomes in this setting. Our data stand in contrast to a previous case series of use of tocilizumab in 15 patients with varying clinical presentations, from moderate severity to critically ill, in which the authors failed to identify a consistent improvement with use of both single-dose and multiple-dose tocilizumab. 6 However, this case series included a heterogeneous population, including a number of patients already under critical care, and doses of tocilizumab varied considerably (80-600 mg). Of the 15 subjects, 8 were treated concurrently with repeated doses of methylprednisolone. Similarly, another case series cautioning the use of tocilizumab reported that two patients were intubated and mechanically ventilated when they received tocilizumab. 9 Further reports on the use of tocilizumab have provided varying results, with some studies administering tocilizumab to more severe respiratory failure and using multiple does of tocilizumab within 24 h. 10, 11 A study of 21 patients from China reported positive outcomes with tocilizumab. However, this cohort also received lopinavir/ritonavir, corticosteroids and interferon, so it is difficult to determine the true efficacy. 12 Notably, another study demonstrated worse outcomes in patients who were intubated compared to those who were not. 13 Our pre-intensive care approach was more standardized in terms of patient profile, MDT approach and the dose used. None of our patients received other concurrent immunosuppressive therapy, providing a clearer indication of the effect of a single dose of tocilizumab in this setting. Although immunomodulatory therapy carries concerns relating to unwanted effects of immunosuppression, apart from one patient suffering an exacerbation of COPD, we observed no other safety signals.

Our data support opinions that therapeutic approaches directly targeting key cytokines to halt the innate immune response may be an important adjunct in moderate to severe cases of COVID-19. 14 We demonstrate a marked reduction in the levels of CRP, ferritin and fibrinogen following tocilizumab therapy. While the reduction in CRP levels is likely a direct effect of tocilizumab, the other markers may be more representative of a change in inflammatory state. Interestingly, changes in serum LDH in our series did not track with reductions observed in other inflammatory markers and it is therefore unclear if LDH accurately reflects IL-6-driven inflammation in this case series. Of note, in this cohort, all patients had elevated body mass index (BMI). It is known that IL-6 levels correlate with BMI and that enhanced IL-6 signalling drives inflammation in obesity. 15 A limitation of this report is that serum IL-6 levels were not measured, as this was not a routinely This report adds to the need for data on the potential efficacy of tocilizumab as an approach for cytokine release associated with COVID-19. The fact that all individuals receiving tocilizumab in this study avoided the need for mechanical ventilation, despite being critically unwell, is encouraging. Nevertheless, interpretation of the results require caution due to several other considerations, including the cohort being small, the patient group being relatively young and the absence of an appropriately matched control group. Hence, to determine the true efficacy and safety of tocilizumab in COVID-19, randomized controlled trials are needed. 

Case-fatality rate and characteristics of patients dying in relation to covid-19 in italy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in

Management of cytokine release syndrome related to CAR-T cell therapy

Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still's disease: a case-based review

Tocilizumab treatment in COVID-19: a single center experience

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report

Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS

Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Effective treatment of severe COVID-19 patients with tocilizumab

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

COVID-19: consider cytokine storm syndromes and immunosuppression

Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance

Additional supplementary information can be accessed via the html version of this article at the publisher's website. Table S1 . Laboratory results.